论文部分内容阅读
目的:研究LAIR-1在肿瘤患者中的表达,探讨其在抗肿瘤免疫应答中的作用。方法:应用夹心ELISA检测肿瘤患者血清中可溶型sLAIR-1的水平;应用免疫荧光染色和流式细胞术分析,观察LAIR-1在患者PBMC中NK细胞、CD4+T细胞、CD8+T细胞和B细胞上的表达。结果:肿瘤患者血清sLAIR-1水平为(4.6±3.2)μg/L,明显高于正常人血清sLAIR-1水平(3.9±3.0)μg/L,P<0.05。NK细胞,CD4+T细胞及CD8+T细胞表达LAIR-1水平上调。肺癌患者CD4/CD8比值明显低于正常人,B细胞百分率明显高于正常人。NK细胞、CD4+T细胞CD8+T细胞中LAIR-1的表达阳性率高于对照组。结论:在肿瘤患者LAIR-1分子表达水平高于正常人。肿瘤患者抑制性受体LAIR-1表达水平的上调可能与肿瘤的免疫逃逸有关。
Objective: To investigate the expression of LAIR-1 in cancer patients and to explore its role in anti-tumor immune response. Methods: The level of soluble sLAIR-1 in sera of patients with cancer was detected by sandwich ELISA. The expressions of NK cells, CD4 + T cells and CD8 + T cells in PBMC of patients were observed by immunofluorescence staining and flow cytometry And B cell expression. Results: The level of sLAIR-1 in cancer patients was (4.6 ± 3.2) μg / L, which was significantly higher than that of sLAIR-1 in normal individuals (3.9 ± 3.0) μg / L, P <0.05. NK cells, CD4 + T cells and CD8 + T cells express LAIR-1 levels. The ratio of CD4 / CD8 in patients with lung cancer was significantly lower than that in normal people, and the percentage of B cells was significantly higher than that in normal people. The positive rate of LAIR-1 in NK cells and CD8 + T cells of CD4 + T cells was higher than that of the control group. Conclusion: The expression of LAIR-1 in cancer patients is higher than that in normal people. The up-regulation of LAIR-1 expression in cancer patients may be related to tumor immune escape.